Hinge Health, Inc.
HNGE
$112.00
+4.18%
Hinge Health, Inc. is a digital healthcare technology company that operates a platform for treating and preventing joint and muscle pain, combining AI-powered motion tracking, wearable sensors, and licensed physical therapists to deliver virtual musculoskeletal (MSK) care to employer and health-plan members. The company sits within the healthcare information services industry as a platform-style disruptor, positioning itself against traditional in-person physical therapy and surgical interventions by offering a lower-cost, digitally delivered alternative for chronic MSK conditions. The current investor narrative centers on the company's rapid post-IPO transformation into a profitable, high-growth enterprise, with recent quarterly results showing revenue growth above 50% year-over-year alongside a swing to meaningful net income and raised guidance. Debate among investors now hinges on whether the stock's dramatic re-rating already discounts future growth, and whether competitive intensity in digital health and the durability of its AI-driven data moat can sustain the current trajectory.…
HNGE
Hinge Health, Inc.
$112.00
Related headlines
HNGE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $112.13 and implied upside of +0.1% versus the current price.
Average Target
$112.13
0 analysts
Implied Upside
+0.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $140
Analyst target range
Hinge Health is covered by 16 analysts, and the consensus is decisively bullish with a recommendation mean of 1.53 (where 1.0 is a Strong Buy) and an overall "buy" rating. The average target price of $112.13 implies roughly 13.1% upside from the current $99.16, a moderate but positive expected return. The consensus leans bullish, supported by a cluster of Buy/Outperform/Overweight ratings from Stifel, Truist, Needham, Citizens, RBC, Evercore ISI, Wells Fargo, and Barclays, with only Baird maintaining a Neutral stance as of September 22, 2026.
The target range spans $90.00 to $140.00, a spread of roughly 55% around the average, which signals meaningful dispersion in analyst conviction. The high target of $140.00 implies approximately 41% upside and likely assumes continued 50%+ revenue growth, further margin expansion toward the mid-20s, and multiple expansion as the company proves its AI-driven moat and platform durability. The low target of $90.00, roughly 9% below the current price, likely prices in growth deceleration, competitive pressure in digital MSK, or margin compression from rising sales and marketing spend. Notably, no analyst has downgraded recently, and the pattern of reiterated Buy ratings following Q2 results suggests stable-to-improving sentiment, though the wide spread and the stock's proximity to consensus targets indicate limited near-term upside unless a new catalyst emerges.
Bulls vs Bears: HNGE Investment Factors
The bull case currently has stronger evidence: 53% revenue growth, a 20.53% net margin, 86.44% gross margin, $287.33M of TTM free cash flow and a 1.53 analyst consensus are hard, verifiable facts, whereas the bear case is largely about price and expectation. The single most important tension is whether 50%+ growth is durable enough to justify a 32.43x forward PE and 6.26x PS after a 128.90% six-month run; if growth holds, the multiple is defensible, but if it decelerates toward 30%, the stock's 48.03% max drawdown history suggests a sharp de-rating. Secondary tension comes from the narrow 13.1% upside to the $112.13 average target versus the $140.00 high target, which implies the market needs a new catalyst to close the gap. Net, the fundamentals support the stock, but the entry point after a near-doubling is the real debate.
Bullish
- Revenue accelerating above 50% YoY: Q2 2026 revenue of $212.82M grew 53% year-over-year from $139.10M and 24.7% sequentially from $182.31M in Q1 2026. This is acceleration, not deceleration, and it is being delivered with expanding margins rather than bought with losses.
- Profitability inflection is real and sequential: Net income of $43.69M (20.53% net margin) in Q2 2026 versus a $575.65M loss a year earlier, with operating margin climbing from 15.96% (Q4 2025) to 17.59% (Q1 2026) to 19.00% (Q2 2026). Gross margin of 86.44% is up from 70.28% a year ago, showing genuine operating leverage.
- Cash generation and fortress balance sheet: TTM free cash flow of $287.33M against a $3.68B market cap implies roughly a 7.8% FCF yield, while debt-to-equity is just 0.021 and the current ratio is 1.47. The company funded $1.85M of capex and $26.53M of buybacks from operating cash flow of $101.41M in Q2 alone.
- Analyst consensus firmly bullish: 16 analysts carry a recommendation mean of 1.53 (Buy) with an average target of $112.13, about 13.1% above the $99.16 price, and a high target of $140.00 implying ~41% upside. Eight-plus houses (Stifel, Truist, Needham, RBC, Evercore ISI, Wells Fargo, Barclays) are positive with only Baird Neutral.
Bearish
- Stock is extended near 52-week highs: At $99.16 the stock sits at roughly 89% of its $30.08-$107.00 range after a 128.90% six-month and 117.65% YTD run, far ahead of the S&P 500's 7.48% and 11.93%. The 5.53% single-day drop from $104.96 on October 16 is a warning that profit-taking can be violent at these levels.
- Valuation still carries a growth premium: A 6.26x PS, 11.23x EV/Sales, 9.72x price-to-book and 32.43x forward PE are rich for a company with limited tangible assets and a 0.021 debt-to-equity ratio. The premium is only defensible if growth stays above 30% and margins keep expanding; any deceleration would compress the multiple sharply.
- History of severe drawdowns: The stock has a 48.03% maximum drawdown, and it fell from $90.00 on July 13 to $74.31 by July 24, a roughly 17% slide in under two weeks. High beta and a short ratio of 3.39 mean position sizing must account for outsized volatility relative to the market.
- Consensus target leaves thin upside: The $112.13 average target implies only ~13.1% upside, and the $90.00 low target sits 9% below the current price. With the stock already near consensus, near-term returns depend on a fresh catalyst rather than multiple re-rating.
HNGE Technical Analysis
Hinge Health is in a powerful, sustained uptrend, with the stock up 95.43% over the past year and an extraordinary 128.90% over six months, dramatically outpacing the S&P 500's 15.53% and 7.48% respective gains. At a current price of $99.16, the stock sits at roughly 89% of its 52-week range of $30.08 to $107.00, positioning it near the upper end of its trading band. This proximity to highs signals strong momentum and market conviction, but also raises the risk of overextension after such a steep advance, particularly given the stock's 48.03% maximum drawdown history, which underscores its capacity for sharp reversals.
Short-term momentum remains positive but is decelerating relative to the longer-term trend. The stock gained 5.79% over the past month and 13.86% over three months, both well ahead of the S&P 500's 1.22% and 2.69%, yielding relative strength of 4.57 and 11.17 percentage points respectively. However, the most recent session saw a sharp 5.53% single-day decline from a previous close of $104.96 to $99.16, suggesting profit-taking near the highs. This pullback, coming after the stock touched $105.14 on October 13, may represent a temporary consolidation rather than a trend reversal, but the velocity of the drop warrants monitoring for follow-through selling.
Key technical support rests at the 52-week low of $30.08, though nearer-term support likely sits around the $90-$92 zone where the stock consolidated in August and September. Resistance is defined by the 52-week high of $107.00, and a decisive breakout above that level would confirm the uptrend's continuation and likely invite momentum-driven buying. A breakdown below $90 would signal weakening conviction and could open the door to a deeper mean-reversion move. With a short ratio of 3.39, short interest is moderate, and the stock's high beta implied by its 48.03% max drawdown and outsized relative strength means position sizing should account for elevated volatility relative to the broader market.
Beta
—
—
Max Drawdown
-47.7%
Largest decline past year
52-Week Range
$30-$112
Price range past year
Annual Return
+125.2%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +18.6% | -0.1% |
| 3m | +46.0% | +4.7% |
| 6m | +152.9% | +8.3% |
| 1y | +125.2% | +15.2% |
| ytd | +145.8% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Hinge Health's revenue trajectory is one of accelerating, high-velocity growth. Most recent quarterly revenue for Q2 2026 reached $212.82 million, up 53% year-over-year, building on a clear sequential cadence: $170.73 million in Q4 2025, $182.31 million in Q1 2026, and $212.82 million in Q2 2026. This represents roughly 24.7% sequential growth from Q1 to Q2 alone, and the year-over-year acceleration from the prior year's $139.10 million Q2 2025 base confirms the business is scaling rapidly rather than decelerating. The company operates as a single reportable segment, so growth is broad-based across its digital MSK platform, and this trajectory supports a compelling investment case built on expanding employer and health-plan adoption.
Profitability has inflected decisively. Q2 2026 net income was $43.69 million, a 20.53% net margin, a dramatic reversal from the $575.65 million loss in Q2 2025 that was driven largely by a $590.98 million stock-based compensation charge tied to the IPO. Gross margin stands at a strong 86.44% in Q2 2026, up from 70.28% a year earlier and 84.45% in Q4 2025, reflecting operating leverage and a favorable mix shift toward higher-margin platform revenue. Operating margin reached 19.00% in Q2 2026 versus negative 417.45% a year prior, and the sequential progression from 15.96% in Q4 2025 to 17.59% in Q1 2026 to 19.00% in Q2 2026 shows consistent margin expansion that is atypical for a recently public healthcare technology company.
The balance sheet is exceptionally clean and cash-generative. Debt-to-equity is just 0.021, current ratio is 1.47, and the company generated $287.33 million in trailing twelve-month free cash flow against a $3.68 billion market cap, implying a robust FCF yield of roughly 7.8%. Operating cash flow of $101.41 million in Q2 2026 comfortably funded $1.85 million in capex, and the company returned capital via $26.53 million in stock repurchases while still growing its cash balance to $287.67 million. ROE of negative 139.55% is a distortion from the IPO-related equity accounting and prior losses, while ROA of 7.70% reflects the improving earnings base; the company clearly funds growth internally with no dependence on external financing.
Quarterly Revenue
$212817000.0B
2026-06
Revenue YoY Growth
+53.0%
YoY Comparison
Gross Margin
86.4%
Latest Quarter
Free Cash Flow
$287327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Because trailing net income is negative on a TTM basis (EPS of -$0.14 and a trailing PE of -8.67x), the trailing PE ratio is not a meaningful primary metric. Instead, the forward PE of 32.43x is the most informative earnings-based measure, as it reflects the market's expectation that the company's profitability inflection is durable; the enormous gap between the negative trailing PE and the positive forward PE signals that consensus expects a sharp earnings ramp. The PS ratio of 6.26x and EV/Sales of 11.23x provide complementary context, with the EV/Sales multiple elevated because the enterprise value calculation appears to incorporate a different share count than the current market cap of $3.68 billion.
Relative to the healthcare information services industry, Hinge Health's 6.26x PS ratio and 32.43x forward PE represent a meaningful premium, consistent with a high-growth, high-margin platform business rather than a mature services provider. The 86.44% gross margin and 53% revenue growth justify a growth premium, but the 9.72x price-to-book ratio is rich for a company with a 0.021 debt-to-equity ratio and limited tangible assets. The premium is defensible only if growth sustains above 30% and margins continue expanding; any deceleration would likely compress the multiple sharply given the stock's already elevated valuation.
Historically, Hinge Health's valuation multiples have compressed dramatically as earnings have inflected. The PS ratio has fallen from 30.73x in Q2 2026's historical ratio snapshot and 25.10x in Q3 2025 to the current 6.26x, while the PE ratio has moved from 37.73x to a forward 32.43x. This compression reflects the market repricing the stock on a forward-earnings basis rather than a revenue basis, and the current PS of 6.26x sits near the low end of its own historical band, suggesting the valuation is no longer stretched relative to its own history even as the stock price has nearly doubled. That dynamic implies the market is pricing in continued earnings delivery rather than pure multiple expansion.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are modest but not zero. The balance sheet is exceptionally clean with debt-to-equity of 0.021, a current ratio of 1.47 and $287.67M of cash, so solvency is not a concern; the real risk is earnings quality and concentration. The Q2 2025 loss of $575.65M was driven by a $590.98M IPO-related stock-based compensation charge, and the swing to $43.69M of net income in Q2 2026 means the profitability story is young and could be sensitive to SBC normalization, sales-and-marketing intensity ($81.41M in Q2 2026, up from $68.80M in Q1) and the durability of 86.44% gross margins. A single-segment business dependent on employer and health-plan adoption also carries customer-concentration and renewal risk that is not visible in the aggregate numbers.
Market and competitive risks center on valuation compression. At 32.43x forward PE, 6.26x PS and 11.23x EV/Sales, HNGE trades at a clear premium to the healthcare information services industry, and the 9.72x price-to-book is rich for an asset-light platform. The stock's beta is effectively high, evidenced by a 48.03% max drawdown and a 17% slide between July 13 and July 24, 2026, so any sector rotation out of high-multiple digital health names would hit hard. Zacks' September 21, 2026 Hold note cites fierce digital-health competition and argues growth is already priced in, while the AI moat's reliance on proprietary patient movement data is an advantage that competitors and traditional physical therapy providers will actively contest.
The worst-case scenario is a growth deceleration combined with multiple compression: if Q3 revenue growth slips toward 30% and margins stall near 19%, the forward PE could compress toward the low-20s, dragging the stock toward the $90.00 analyst low target, about 9% below the current $99.16. A deeper de-rating toward the August-September consolidation zone of $90-$92 would be the first stop, and a full mean-reversion move toward the $30.08 52-week low would represent a roughly 70% loss, though that extreme is unlikely without a fundamental break. A more realistic adverse case is a 20-30% drawdown to the $70-$80 area, consistent with the July 2026 pullback to $74.31, which would still be painful for anyone buying near $99.